Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells.


Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
10 04 2019
Historique:
received: 02 08 2018
revised: 21 12 2018
accepted: 11 01 2019
pubmed: 21 1 2019
medline: 18 12 2019
entrez: 21 1 2019
Statut: ppublish

Résumé

Cannabidiol (CBD), one of the compounds present in the marijuana plant, has anti-tumor properties, but its mechanism is not well known. This study aimed to evaluate the apoptotic action of CBD in colorectal cancer (CRC) cells, and focused on its effects on the novel pro-apoptotic Noxa-reactive oxygen species (ROS) signaling pathway. CBD experiments were performed using the CRC cell lines HCT116 and DLD-1. CBD induced apoptosis by regulating many pro- and anti-apoptotic proteins, of which Noxa showed significantly higher expression. To understand the relationship between Noxa and CBD-induced apoptosis, Noxa levels were downregulated using siRNA, and the expression of apoptosis markers decreased. After ROS production was blocked, the level of Noxa also decreased, suggesting that ROS is involved in the regulation of Noxa, which along with ROS is a well-known pro-apoptotic signaling agents. As a result, CBD induced apoptosis in a Noxa-and-ROS-dependent manner. Taken together, the results obtained in this study re-demonstrated the effects of CBD treatment in vivo, thus confirming its role as a novel, reliable anticancer drug.

Identifiants

pubmed: 30660647
pii: S0304-3835(19)30023-0
doi: 10.1016/j.canlet.2019.01.011
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Apoptosis Regulatory Proteins 0
PMAIP1 protein, human 0
Proto-Oncogene Proteins c-bcl-2 0
Reactive Oxygen Species 0
Cannabidiol 19GBJ60SN5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-23

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Soyeon Jeong (S)

Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.

Hye Kyeong Yun (HK)

Graduate School of Medicine, College of Medicine, Korea University, Seoul, 08308, Republic of Korea.

Yoon A Jeong (YA)

Graduate School of Medicine, College of Medicine, Korea University, Seoul, 08308, Republic of Korea.

Min Jee Jo (MJ)

Graduate School of Medicine, College of Medicine, Korea University, Seoul, 08308, Republic of Korea.

Sang Hee Kang (SH)

Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.

Jung Lim Kim (JL)

Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.

Dae Yeong Kim (DY)

Graduate School of Medicine, College of Medicine, Korea University, Seoul, 08308, Republic of Korea.

Seong Hye Park (SH)

Graduate School of Medicine, College of Medicine, Korea University, Seoul, 08308, Republic of Korea.

Bo Ram Kim (BR)

Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.

Yoo Jin Na (YJ)

Graduate School of Medicine, College of Medicine, Korea University, Seoul, 08308, Republic of Korea.

Sun Il Lee (SI)

Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.

Han Do Kim (HD)

Kaiyon Bio Tech Co., Ltd, 226 Gamasan-Ro, Guro-gu, Seoul, 08308, Republic of Korea.

Dae Hyun Kim (DH)

Kaiyon Bio Tech Co., Ltd, 226 Gamasan-Ro, Guro-gu, Seoul, 08308, Republic of Korea.

Sang Cheul Oh (SC)

Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea; Graduate School of Medicine, College of Medicine, Korea University, Seoul, 08308, Republic of Korea. Electronic address: sachoh@korea.ac.kr.

Dae-Hee Lee (DH)

Department of Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea; Graduate School of Medicine, College of Medicine, Korea University, Seoul, 08308, Republic of Korea. Electronic address: neogene@korea.ac.kr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH